{
    "name": "verteporfin",
    "comment": "Rx",
    "other_names": [
        "Visudyne"
    ],
    "classes": [
        "Macular Degeneration Agents"
    ],
    "source": "https://reference.medscape.com/drug/visudyne-verteporfin-343641",
    "pregnancy": {
        "common": [
            "There are no data with use in pregnant women to inform a drug-associated risk; there are no adequate and well-controlled studies in pregnant women; drug should be used during pregnancy only if benefit justifies potential risk to fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Intravenous administration of drug to pregnant rats during period of organogenesis produced an increase in the incidence of anophthalmia/microphthalmia and wavy ribs at exposures approximately 40-fold the human exposure at recommended clinical dose; drug did not produce adverse fetal effect in rats or rabbits at exposures 6- to 20-fold human exposure at recommended clinical dose;"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "The drug and its diacid metabolite have been found in human breast milk following an intravenous infusion at the recommended human dose of 6 mg/m2; the drug was present in breast milk at levels up to 66% of the corresponding plasma levels and declined below the limit of quantification (2 ng/mL) within 24 hours",
            "The diacid metabolite had lower peak concentrations but persisted up to at least 48 hours",
            "Because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or postpone treatment, taking into account the importance of the drug to the mother"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity, porphyria"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Avoid bright light for 5 days after injection",
                "Moderate/severe hepatic impairment",
                "Chest pain, hypersensitivity, and vasovagal reactions reported (observe patient during infusion); cases of anaphylactic reactions reported in patients receiving therapy; medical supervision recommended during infusion; if an anaphylactic or other serious allergic reaction occurs during or following infusion, administration should be discontinued immediately, and appropriate therapy initiated",
                "Use with caution in patients with biliary obstruction",
                "Patients under anesthesia not studied",
                "Use in both eyes concurrently not studied (if required, apply to the agressive lesion first followed by the second eye a week later; may apply concurrently to both eyes thereafter)",
                "Use precaution to avoid extravasation (stop infusion immediately if it occurs); extravasation, especially if the affected area is exposed to light, can cause severe pain, inflammation, swelling or discoloration at the injection site; localized (skin) necrosis at injection site following extravasation also reported",
                "Safety and efficacy of use >2 years not established",
                "Patients who experience severe decrease of vision of 4 lines or more within 1 week, following treatment, should not be retreated, at least until vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by treating physician"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid oral",
            "description": {
                "common": "aminolevulinic acid oral, verteporfin.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid topical",
            "description": {
                "common": "verteporfin, aminolevulinic acid topical.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methyl aminolevulinate",
            "description": {
                "common": "verteporfin, methyl aminolevulinate.\nEither increases levels of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "beta carotene",
            "description": {
                "common": "beta carotene decreases effects of verteporfin by pharmacodynamic antagonism. Use Caution/Monitor. Drugs that reduce active oxygen species or scavenge radicals are expected to decrease verteporfin's therapeutic effect ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranibizumab intravitreal injection",
            "description": {
                "common": "ranibizumab intravitreal injection increases toxicity of verteporfin by unspecified interaction mechanism. Use Caution/Monitor. Risk of severe intraocular inflammation, even when separated by 7 days."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and verteporfin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "abciximab",
            "description": {
                "common": "abciximab decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amlodipine",
            "description": {
                "common": "amlodipine increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anagrelide",
            "description": {
                "common": "anagrelide decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antioxidants",
            "description": {
                "common": "antioxidants decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "antithrombin alfa decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "antithrombin III decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "argatroban",
            "description": {
                "common": "argatroban decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bemiparin",
            "description": {
                "common": "bemiparin decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "bendroflumethiazide, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "bivalirudin decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cilostazol",
            "description": {
                "common": "cilostazol decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clevidipine",
            "description": {
                "common": "clevidipine increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "clopidogrel decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dabigatran",
            "description": {
                "common": "dabigatran decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dalteparin",
            "description": {
                "common": "dalteparin decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "demeclocycline, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "dipyridamole decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "enoxaparin decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eptifibatide",
            "description": {
                "common": "eptifibatide decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felodipine",
            "description": {
                "common": "felodipine increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "fondaparinux decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "heparin",
            "description": {
                "common": "heparin decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "isradipine increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methyclothiazide, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "metolazone, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "minocycline",
            "description": {
                "common": "minocycline, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "nisoldipine increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "oxytetracycline, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenindione",
            "description": {
                "common": "phenindione decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "polymyxin B increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prasugrel",
            "description": {
                "common": "prasugrel decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protamine",
            "description": {
                "common": "protamine decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "radiation",
            "description": {
                "common": "radiation increases levels of verteporfin by Other (see comment). Minor/Significance Unknown. \nComment: Radiation may enhance tissue uptake of verteporfin."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "sulfadiazine, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "sulfisoxazole, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "ticlopidine decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tirofiban",
            "description": {
                "common": "tirofiban decreases effects of verteporfin by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Visual disturbances",
            "percent": "1-4"
        },
        {
            "name": "Injection site reactions including extravasation and rashes",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Hemorrhage",
            "percent": null
        },
        {
            "name": "Inflammation",
            "percent": null
        },
        {
            "name": "Flashes of light",
            "percent": null
        },
        {
            "name": "Severe vision loss",
            "percent": null
        },
        {
            "name": "Photosensitivity",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Dry eyes",
            "percent": null
        },
        {
            "name": "Ocular itching",
            "percent": null
        },
        {
            "name": "Subconjunctival",
            "percent": null
        },
        {
            "name": "Subretinal or vitreous hemorrhage",
            "percent": null
        },
        {
            "name": "Back pain during infusion",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Flu",
            "percent": null
        },
        {
            "name": "like syndrome",
            "percent": null
        },
        {
            "name": "Atrial fibrillation",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Peripheral vascular disorder",
            "percent": null
        },
        {
            "name": "Varicose veins",
            "percent": null
        },
        {
            "name": "Eczema",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "GI cancers",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "WBC incr",
            "percent": null
        },
        {
            "name": "decr",
            "percent": null
        },
        {
            "name": "Elev LFTs",
            "percent": null
        },
        {
            "name": "Albuminuria",
            "percent": null
        },
        {
            "name": "Leukocyte count increase",
            "percent": null
        },
        {
            "name": "decrease",
            "percent": null
        },
        {
            "name": "Increased liver function test results",
            "percent": null
        },
        {
            "name": "Albuminuria",
            "percent": null
        },
        {
            "name": "Increased serum creatinine",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Arthrosis",
            "percent": null
        },
        {
            "name": "Myasthenia",
            "percent": null
        },
        {
            "name": "Hypesthesia",
            "percent": null
        },
        {
            "name": "Sleep disorder",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Pharyngitis",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Hearing decrease",
            "percent": null
        },
        {
            "name": "Lacrimation disorder",
            "percent": null
        },
        {
            "name": "Prostatic disorder",
            "percent": null
        }
    ]
}